nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—HTR2C—Sorafenib—thyroid cancer	0.143	0.227	CbGbCtD
Nefazodone—CYP3A7—Sorafenib—thyroid cancer	0.0934	0.148	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.0934	0.148	CbGbCtD
Nefazodone—CYP3A5—Sorafenib—thyroid cancer	0.07	0.111	CbGbCtD
Nefazodone—ABCB1—Sorafenib—thyroid cancer	0.0456	0.0722	CbGbCtD
Nefazodone—CYP3A4—Vandetanib—thyroid cancer	0.0453	0.0718	CbGbCtD
Nefazodone—CYP2D6—Sorafenib—thyroid cancer	0.0429	0.068	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—thyroid cancer	0.0277	0.0438	CbGbCtD
Nefazodone—CYP3A4—Sorafenib—thyroid cancer	0.0273	0.0432	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—thyroid cancer	0.0261	0.0413	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—thyroid cancer	0.0166	0.0262	CbGbCtD
Nefazodone—Constipation—Sorafenib—thyroid cancer	0.000601	0.0017	CcSEcCtD
Nefazodone—Pain—Sorafenib—thyroid cancer	0.000601	0.0017	CcSEcCtD
Nefazodone—Hypertonia—Doxorubicin—thyroid cancer	0.00059	0.00167	CcSEcCtD
Nefazodone—Hepatic failure—Epirubicin—thyroid cancer	0.000588	0.00166	CcSEcCtD
Nefazodone—Eczema—Epirubicin—thyroid cancer	0.000588	0.00166	CcSEcCtD
Nefazodone—Abnormal vision—Doxorubicin—thyroid cancer	0.000587	0.00166	CcSEcCtD
Nefazodone—Eye pain—Epirubicin—thyroid cancer	0.000585	0.00165	CcSEcCtD
Nefazodone—Mental disability—Doxorubicin—thyroid cancer	0.000585	0.00165	CcSEcCtD
Nefazodone—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000583	0.00165	CcSEcCtD
Nefazodone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000575	0.00162	CcSEcCtD
Nefazodone—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000573	0.00162	CcSEcCtD
Nefazodone—Increased appetite—Epirubicin—thyroid cancer	0.000562	0.00159	CcSEcCtD
Nefazodone—Urticaria—Sorafenib—thyroid cancer	0.000558	0.00158	CcSEcCtD
Nefazodone—Abdominal pain—Sorafenib—thyroid cancer	0.000556	0.00157	CcSEcCtD
Nefazodone—Body temperature increased—Sorafenib—thyroid cancer	0.000556	0.00157	CcSEcCtD
Nefazodone—Dermatitis bullous—Epirubicin—thyroid cancer	0.000553	0.00156	CcSEcCtD
Nefazodone—Eczema—Doxorubicin—thyroid cancer	0.000544	0.00154	CcSEcCtD
Nefazodone—Hepatic failure—Doxorubicin—thyroid cancer	0.000544	0.00154	CcSEcCtD
Nefazodone—Eye pain—Doxorubicin—thyroid cancer	0.000542	0.00153	CcSEcCtD
Nefazodone—Hypoglycaemia—Epirubicin—thyroid cancer	0.000541	0.00153	CcSEcCtD
Nefazodone—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000539	0.00152	CcSEcCtD
Nefazodone—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000539	0.00152	CcSEcCtD
Nefazodone—Hyponatraemia—Epirubicin—thyroid cancer	0.000531	0.0015	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000528	0.00149	CcSEcCtD
Nefazodone—Osteoarthritis—Epirubicin—thyroid cancer	0.000528	0.00149	CcSEcCtD
Nefazodone—Diplopia—Epirubicin—thyroid cancer	0.000528	0.00149	CcSEcCtD
Nefazodone—Increased appetite—Doxorubicin—thyroid cancer	0.00052	0.00147	CcSEcCtD
Nefazodone—Affect lability—Epirubicin—thyroid cancer	0.00052	0.00147	CcSEcCtD
Nefazodone—Migraine—Epirubicin—thyroid cancer	0.00052	0.00147	CcSEcCtD
Nefazodone—Hypersensitivity—Sorafenib—thyroid cancer	0.000518	0.00146	CcSEcCtD
Nefazodone—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000512	0.00145	CcSEcCtD
Nefazodone—Face oedema—Epirubicin—thyroid cancer	0.00051	0.00144	CcSEcCtD
Nefazodone—Asthenia—Sorafenib—thyroid cancer	0.000504	0.00142	CcSEcCtD
Nefazodone—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000501	0.00142	CcSEcCtD
Nefazodone—Mood swings—Epirubicin—thyroid cancer	0.000501	0.00141	CcSEcCtD
Nefazodone—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000499	0.00141	CcSEcCtD
Nefazodone—Pruritus—Sorafenib—thyroid cancer	0.000497	0.00141	CcSEcCtD
Nefazodone—Ataxia—Epirubicin—thyroid cancer	0.000497	0.0014	CcSEcCtD
Nefazodone—Dehydration—Epirubicin—thyroid cancer	0.000491	0.00139	CcSEcCtD
Nefazodone—Hyponatraemia—Doxorubicin—thyroid cancer	0.000491	0.00139	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000489	0.00138	CcSEcCtD
Nefazodone—Osteoarthritis—Doxorubicin—thyroid cancer	0.000489	0.00138	CcSEcCtD
Nefazodone—Diplopia—Doxorubicin—thyroid cancer	0.000489	0.00138	CcSEcCtD
Nefazodone—Liver function test abnormal—Epirubicin—thyroid cancer	0.000488	0.00138	CcSEcCtD
Nefazodone—Dry skin—Epirubicin—thyroid cancer	0.000484	0.00137	CcSEcCtD
Nefazodone—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000483	0.00136	CcSEcCtD
Nefazodone—Affect lability—Doxorubicin—thyroid cancer	0.000481	0.00136	CcSEcCtD
Nefazodone—Migraine—Doxorubicin—thyroid cancer	0.000481	0.00136	CcSEcCtD
Nefazodone—Diarrhoea—Sorafenib—thyroid cancer	0.000481	0.00136	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000476	0.00134	CcSEcCtD
Nefazodone—Face oedema—Doxorubicin—thyroid cancer	0.000472	0.00133	CcSEcCtD
Nefazodone—Gastritis—Epirubicin—thyroid cancer	0.000468	0.00132	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000466	0.00132	CcSEcCtD
Nefazodone—Dizziness—Sorafenib—thyroid cancer	0.000465	0.00131	CcSEcCtD
Nefazodone—Mood swings—Doxorubicin—thyroid cancer	0.000463	0.00131	CcSEcCtD
Nefazodone—Abdominal distension—Epirubicin—thyroid cancer	0.00046	0.0013	CcSEcCtD
Nefazodone—Ataxia—Doxorubicin—thyroid cancer	0.00046	0.0013	CcSEcCtD
Nefazodone—Influenza—Epirubicin—thyroid cancer	0.000457	0.00129	CcSEcCtD
Nefazodone—Asthma—Epirubicin—thyroid cancer	0.000457	0.00129	CcSEcCtD
Nefazodone—Dysphagia—Epirubicin—thyroid cancer	0.000457	0.00129	CcSEcCtD
Nefazodone—Dehydration—Doxorubicin—thyroid cancer	0.000455	0.00129	CcSEcCtD
Nefazodone—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000451	0.00128	CcSEcCtD
Nefazodone—Dry skin—Doxorubicin—thyroid cancer	0.000448	0.00127	CcSEcCtD
Nefazodone—Vomiting—Sorafenib—thyroid cancer	0.000447	0.00126	CcSEcCtD
Nefazodone—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000447	0.00126	CcSEcCtD
Nefazodone—Angina pectoris—Epirubicin—thyroid cancer	0.000445	0.00126	CcSEcCtD
Nefazodone—Rash—Sorafenib—thyroid cancer	0.000443	0.00125	CcSEcCtD
Nefazodone—Dermatitis—Sorafenib—thyroid cancer	0.000443	0.00125	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00044	0.00124	CcSEcCtD
Nefazodone—Headache—Sorafenib—thyroid cancer	0.00044	0.00124	CcSEcCtD
Nefazodone—Bronchitis—Epirubicin—thyroid cancer	0.000439	0.00124	CcSEcCtD
Nefazodone—Gastritis—Doxorubicin—thyroid cancer	0.000433	0.00122	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000431	0.00122	CcSEcCtD
Nefazodone—Dysuria—Epirubicin—thyroid cancer	0.000427	0.00121	CcSEcCtD
Nefazodone—Abdominal distension—Doxorubicin—thyroid cancer	0.000425	0.0012	CcSEcCtD
Nefazodone—Asthma—Doxorubicin—thyroid cancer	0.000423	0.00119	CcSEcCtD
Nefazodone—Influenza—Doxorubicin—thyroid cancer	0.000423	0.00119	CcSEcCtD
Nefazodone—Dysphagia—Doxorubicin—thyroid cancer	0.000423	0.00119	CcSEcCtD
Nefazodone—Pollakiuria—Epirubicin—thyroid cancer	0.000422	0.00119	CcSEcCtD
Nefazodone—Nausea—Sorafenib—thyroid cancer	0.000417	0.00118	CcSEcCtD
Nefazodone—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000417	0.00118	CcSEcCtD
Nefazodone—Weight increased—Epirubicin—thyroid cancer	0.000416	0.00117	CcSEcCtD
Nefazodone—Weight decreased—Epirubicin—thyroid cancer	0.000413	0.00117	CcSEcCtD
Nefazodone—Angina pectoris—Doxorubicin—thyroid cancer	0.000412	0.00116	CcSEcCtD
Nefazodone—Pneumonia—Epirubicin—thyroid cancer	0.00041	0.00116	CcSEcCtD
Nefazodone—Bronchitis—Doxorubicin—thyroid cancer	0.000406	0.00115	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000404	0.00114	CcSEcCtD
Nefazodone—Stomatitis—Epirubicin—thyroid cancer	0.000397	0.00112	CcSEcCtD
Nefazodone—Urinary tract infection—Epirubicin—thyroid cancer	0.000396	0.00112	CcSEcCtD
Nefazodone—Conjunctivitis—Epirubicin—thyroid cancer	0.000396	0.00112	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—thyroid cancer	0.000395	0.00112	CcSEcCtD
Nefazodone—Sweating—Epirubicin—thyroid cancer	0.00039	0.0011	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—thyroid cancer	0.00039	0.0011	CcSEcCtD
Nefazodone—Haematuria—Epirubicin—thyroid cancer	0.000388	0.0011	CcSEcCtD
Nefazodone—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000386	0.00109	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—thyroid cancer	0.000385	0.00109	CcSEcCtD
Nefazodone—Epistaxis—Epirubicin—thyroid cancer	0.000384	0.00109	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—thyroid cancer	0.000382	0.00108	CcSEcCtD
Nefazodone—Sinusitis—Epirubicin—thyroid cancer	0.000382	0.00108	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—thyroid cancer	0.000379	0.00107	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000374	0.00106	CcSEcCtD
Nefazodone—Bradycardia—Epirubicin—thyroid cancer	0.000372	0.00105	CcSEcCtD
Nefazodone—Haemoglobin—Epirubicin—thyroid cancer	0.000367	0.00104	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—thyroid cancer	0.000367	0.00104	CcSEcCtD
Nefazodone—Rhinitis—Epirubicin—thyroid cancer	0.000366	0.00104	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—thyroid cancer	0.000366	0.00104	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—thyroid cancer	0.000366	0.00104	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—thyroid cancer	0.000366	0.00103	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—thyroid cancer	0.000366	0.00103	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—thyroid cancer	0.000364	0.00103	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—thyroid cancer	0.000363	0.00103	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—thyroid cancer	0.000361	0.00102	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—thyroid cancer	0.00036	0.00102	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—thyroid cancer	0.000359	0.00102	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—thyroid cancer	0.000355	0.001	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—thyroid cancer	0.000354	0.000999	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—thyroid cancer	0.000352	0.000996	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—thyroid cancer	0.000346	0.000977	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—thyroid cancer	0.000344	0.000973	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—thyroid cancer	0.000341	0.000963	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—thyroid cancer	0.00034	0.000961	CcSEcCtD
Nefazodone—Flushing—Epirubicin—thyroid cancer	0.000339	0.000959	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—thyroid cancer	0.000339	0.000958	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—thyroid cancer	0.000338	0.000956	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—thyroid cancer	0.000338	0.000956	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000337	0.000951	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—thyroid cancer	0.000336	0.000949	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—thyroid cancer	0.000333	0.000942	CcSEcCtD
Nefazodone—Chills—Epirubicin—thyroid cancer	0.000328	0.000927	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—thyroid cancer	0.000326	0.000921	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—thyroid cancer	0.000323	0.000913	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—thyroid cancer	0.00032	0.000904	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—thyroid cancer	0.000315	0.000891	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—thyroid cancer	0.000314	0.000887	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—thyroid cancer	0.000314	0.000886	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—thyroid cancer	0.000312	0.000881	CcSEcCtD
Nefazodone—Back pain—Epirubicin—thyroid cancer	0.000308	0.00087	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—thyroid cancer	0.000306	0.000865	CcSEcCtD
Nefazodone—Chills—Doxorubicin—thyroid cancer	0.000304	0.000858	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—thyroid cancer	0.0003	0.000848	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—thyroid cancer	0.000299	0.000845	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—thyroid cancer	0.000295	0.000834	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—thyroid cancer	0.000294	0.000831	CcSEcCtD
Nefazodone—Agitation—Epirubicin—thyroid cancer	0.000292	0.000826	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—thyroid cancer	0.00029	0.00082	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—thyroid cancer	0.000288	0.000815	CcSEcCtD
Nefazodone—Malaise—Epirubicin—thyroid cancer	0.000287	0.000811	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—thyroid cancer	0.000286	0.000808	CcSEcCtD
Nefazodone—Syncope—Epirubicin—thyroid cancer	0.000285	0.000807	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—thyroid cancer	0.000285	0.000805	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—thyroid cancer	0.000285	0.000805	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—thyroid cancer	0.000283	0.0008	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—thyroid cancer	0.000281	0.000795	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—thyroid cancer	0.00028	0.00079	CcSEcCtD
Nefazodone—Cough—Epirubicin—thyroid cancer	0.000278	0.000785	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—thyroid cancer	0.000278	0.000784	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—thyroid cancer	0.000276	0.000779	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—thyroid cancer	0.000275	0.000776	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000273	0.000772	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—thyroid cancer	0.000272	0.000769	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—thyroid cancer	0.000271	0.000766	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—thyroid cancer	0.000271	0.000766	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—thyroid cancer	0.000271	0.000766	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—thyroid cancer	0.000271	0.000765	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—thyroid cancer	0.00027	0.000763	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—thyroid cancer	0.000268	0.000756	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—thyroid cancer	0.000266	0.00075	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—thyroid cancer	0.000265	0.000749	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—thyroid cancer	0.000265	0.000748	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—thyroid cancer	0.000264	0.000746	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—thyroid cancer	0.000264	0.000745	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—thyroid cancer	0.000262	0.00074	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—thyroid cancer	0.00026	0.000735	CcSEcCtD
Nefazodone—Oedema—Epirubicin—thyroid cancer	0.00026	0.000734	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—thyroid cancer	0.00026	0.000734	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—thyroid cancer	0.000259	0.000731	CcSEcCtD
Nefazodone—Infection—Epirubicin—thyroid cancer	0.000258	0.000729	CcSEcCtD
Nefazodone—Cough—Doxorubicin—thyroid cancer	0.000257	0.000726	CcSEcCtD
Nefazodone—Shock—Epirubicin—thyroid cancer	0.000256	0.000722	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—thyroid cancer	0.000255	0.000721	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—thyroid cancer	0.000254	0.000719	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—thyroid cancer	0.000254	0.000718	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—thyroid cancer	0.000253	0.000716	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—thyroid cancer	0.000251	0.00071	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—thyroid cancer	0.000251	0.000708	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—thyroid cancer	0.000251	0.000708	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—thyroid cancer	0.000251	0.000708	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—thyroid cancer	0.00025	0.000706	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—thyroid cancer	0.000248	0.0007	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—thyroid cancer	0.000248	0.0007	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—thyroid cancer	0.000245	0.000693	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—thyroid cancer	0.000243	0.000686	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—thyroid cancer	0.000242	0.000685	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—thyroid cancer	0.00024	0.000679	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00024	0.000679	CcSEcCtD
Nefazodone—Infection—Doxorubicin—thyroid cancer	0.000239	0.000675	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000237	0.000669	CcSEcCtD
Nefazodone—Shock—Doxorubicin—thyroid cancer	0.000236	0.000668	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000235	0.000665	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—thyroid cancer	0.000235	0.000664	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—thyroid cancer	0.000235	0.000663	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—thyroid cancer	0.000233	0.000659	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000232	0.000657	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—thyroid cancer	0.000232	0.000654	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—thyroid cancer	0.000231	0.000653	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—thyroid cancer	0.000229	0.000647	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—thyroid cancer	0.000229	0.000646	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—thyroid cancer	0.000226	0.000638	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—thyroid cancer	0.000225	0.000635	CcSEcCtD
Nefazodone—Constipation—Epirubicin—thyroid cancer	0.000222	0.000628	CcSEcCtD
Nefazodone—Pain—Epirubicin—thyroid cancer	0.000222	0.000628	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000219	0.000619	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—thyroid cancer	0.000217	0.000614	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—thyroid cancer	0.000216	0.00061	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—thyroid cancer	0.000214	0.000605	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—thyroid cancer	0.000214	0.000605	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—thyroid cancer	0.000214	0.000604	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000212	0.0006	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—thyroid cancer	0.000212	0.000598	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—thyroid cancer	0.000209	0.00059	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—thyroid cancer	0.000206	0.000583	CcSEcCtD
Nefazodone—Pain—Doxorubicin—thyroid cancer	0.000206	0.000581	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—thyroid cancer	0.000206	0.000581	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—thyroid cancer	0.000205	0.00058	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—thyroid cancer	0.000205	0.00058	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—thyroid cancer	0.000198	0.00056	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000197	0.000555	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—thyroid cancer	0.000191	0.000541	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—thyroid cancer	0.000191	0.00054	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—thyroid cancer	0.00019	0.000537	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—thyroid cancer	0.00019	0.000537	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—thyroid cancer	0.000186	0.000527	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—thyroid cancer	0.000184	0.000519	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—thyroid cancer	0.000178	0.000502	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000177	0.0005	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—thyroid cancer	0.000172	0.000487	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—thyroid cancer	0.000172	0.000485	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—thyroid cancer	0.00017	0.00048	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—thyroid cancer	0.000165	0.000467	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—thyroid cancer	0.000164	0.000465	CcSEcCtD
Nefazodone—Rash—Epirubicin—thyroid cancer	0.000164	0.000463	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—thyroid cancer	0.000164	0.000462	CcSEcCtD
Nefazodone—Headache—Epirubicin—thyroid cancer	0.000163	0.00046	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—thyroid cancer	0.000159	0.000449	CcSEcCtD
Nefazodone—Nausea—Epirubicin—thyroid cancer	0.000154	0.000436	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—thyroid cancer	0.000153	0.000432	CcSEcCtD
Nefazodone—Rash—Doxorubicin—thyroid cancer	0.000152	0.000428	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—thyroid cancer	0.000151	0.000428	CcSEcCtD
Nefazodone—Headache—Doxorubicin—thyroid cancer	0.000151	0.000425	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—thyroid cancer	0.000143	0.000403	CcSEcCtD
Nefazodone—HTR2C—Signaling by GPCR—SST—thyroid cancer	1.72e-05	0.00118	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PRKAR1A—thyroid cancer	1.72e-05	0.00118	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TCF7L1—thyroid cancer	1.71e-05	0.00117	CbGpPWpGaD
Nefazodone—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.69e-05	0.00115	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CALCA—thyroid cancer	1.67e-05	0.00114	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CALCA—thyroid cancer	1.66e-05	0.00113	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—SST—thyroid cancer	1.65e-05	0.00113	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—SST—thyroid cancer	1.65e-05	0.00112	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PTCH1—thyroid cancer	1.64e-05	0.00112	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	1.62e-05	0.0011	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—SST—thyroid cancer	1.61e-05	0.0011	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PTCH1—thyroid cancer	1.6e-05	0.00109	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	1.6e-05	0.00109	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CALCA—thyroid cancer	1.59e-05	0.00108	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CALCA—thyroid cancer	1.59e-05	0.00108	CbGpPWpGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—HRAS—thyroid cancer	1.58e-05	0.00108	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	1.58e-05	0.00108	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—TPR—thyroid cancer	1.57e-05	0.00107	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CALCA—thyroid cancer	1.55e-05	0.00106	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TCF7L1—thyroid cancer	1.55e-05	0.00106	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	1.54e-05	0.00105	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	1.53e-05	0.00105	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TCF7L1—thyroid cancer	1.52e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CDK1—thyroid cancer	1.51e-05	0.00103	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CDK1—thyroid cancer	1.5e-05	0.00103	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—SST—thyroid cancer	1.5e-05	0.00102	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—SST—thyroid cancer	1.5e-05	0.00102	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HPGD—thyroid cancer	1.49e-05	0.00102	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PTCH1—thyroid cancer	1.49e-05	0.00102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—SST—thyroid cancer	1.46e-05	0.001	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CALCA—thyroid cancer	1.44e-05	0.000985	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CALCA—thyroid cancer	1.44e-05	0.000983	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CDK1—thyroid cancer	1.44e-05	0.000981	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.44e-05	0.000981	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.42e-05	0.000972	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TCF7L1—thyroid cancer	1.41e-05	0.000965	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CALCA—thyroid cancer	1.41e-05	0.000963	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HPGD—thyroid cancer	1.4e-05	0.000958	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	1.39e-05	0.00095	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.37e-05	0.000933	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	1.36e-05	0.00093	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	1.36e-05	0.00093	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—SST—thyroid cancer	1.36e-05	0.000929	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TSHR—thyroid cancer	1.32e-05	0.000898	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CALCA—thyroid cancer	1.31e-05	0.000895	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TSHR—thyroid cancer	1.31e-05	0.000894	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CDK1—thyroid cancer	1.3e-05	0.00089	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	1.3e-05	0.00089	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	1.3e-05	0.000886	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PRKAR1A—thyroid cancer	1.29e-05	0.000884	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PRKAR1A—thyroid cancer	1.29e-05	0.000879	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CDK1—thyroid cancer	1.28e-05	0.000872	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TSHR—thyroid cancer	1.25e-05	0.000855	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	1.25e-05	0.000855	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MEN1—thyroid cancer	1.24e-05	0.000845	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—TPR—thyroid cancer	1.24e-05	0.000844	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PRKAR1A—thyroid cancer	1.23e-05	0.000842	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MEN1—thyroid cancer	1.23e-05	0.00084	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PRKAR1A—thyroid cancer	1.22e-05	0.000831	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—HRAS—thyroid cancer	1.21e-05	0.000829	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.21e-05	0.000826	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CDK1—thyroid cancer	1.19e-05	0.00081	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	1.18e-05	0.000807	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MEN1—thyroid cancer	1.18e-05	0.000804	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—SLC5A5—thyroid cancer	1.17e-05	0.000801	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	1.16e-05	0.00079	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.15e-05	0.000784	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CHST14—thyroid cancer	1.14e-05	0.000777	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TSHR—thyroid cancer	1.14e-05	0.000776	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—TPR—thyroid cancer	1.13e-05	0.000774	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTCH1—thyroid cancer	1.12e-05	0.000764	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PRKAR1A—thyroid cancer	1.12e-05	0.000763	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	1.11e-05	0.000761	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTCH1—thyroid cancer	1.11e-05	0.00076	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TSHR—thyroid cancer	1.11e-05	0.00076	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PRKAR1A—thyroid cancer	1.09e-05	0.000748	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MEN1—thyroid cancer	1.07e-05	0.00073	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTCH1—thyroid cancer	1.07e-05	0.000727	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MEN1—thyroid cancer	1.05e-05	0.000714	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TSHR—thyroid cancer	1.03e-05	0.000706	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SST—thyroid cancer	1.02e-05	0.000699	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SST—thyroid cancer	1.02e-05	0.000695	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PRKAR1A—thyroid cancer	1.02e-05	0.000695	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—RXRA—thyroid cancer	9.86e-06	0.000673	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CALCA—thyroid cancer	9.85e-06	0.000672	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CALCA—thyroid cancer	9.79e-06	0.000669	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SST—thyroid cancer	9.74e-06	0.000665	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MEN1—thyroid cancer	9.72e-06	0.000664	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTCH1—thyroid cancer	9.66e-06	0.00066	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	9.62e-06	0.000657	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTCH1—thyroid cancer	9.46e-06	0.000646	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CALCA—thyroid cancer	9.38e-06	0.00064	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	9.29e-06	0.000634	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—SLC5A5—thyroid cancer	9.25e-06	0.000632	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HPGD—thyroid cancer	9.17e-06	0.000626	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDK1—thyroid cancer	8.91e-06	0.000609	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDK1—thyroid cancer	8.87e-06	0.000606	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SST—thyroid cancer	8.84e-06	0.000603	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTCH1—thyroid cancer	8.79e-06	0.0006	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SST—thyroid cancer	8.65e-06	0.000591	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TPR—thyroid cancer	8.55e-06	0.000584	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	8.55e-06	0.000584	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CALCA—thyroid cancer	8.51e-06	0.000581	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDK1—thyroid cancer	8.49e-06	0.00058	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—SLC5A5—thyroid cancer	8.48e-06	0.000579	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PRKAR1A—thyroid cancer	8.41e-06	0.000574	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CALCA—thyroid cancer	8.33e-06	0.000569	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TPR—thyroid cancer	8.06e-06	0.00055	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SST—thyroid cancer	8.04e-06	0.000549	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	7.93e-06	0.000541	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—RXRA—thyroid cancer	7.78e-06	0.000531	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CALCA—thyroid cancer	7.74e-06	0.000528	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDK1—thyroid cancer	7.7e-06	0.000526	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDK1—thyroid cancer	7.54e-06	0.000515	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—NRAS—thyroid cancer	7.41e-06	0.000506	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	7.22e-06	0.000493	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NRG1—thyroid cancer	7.15e-06	0.000489	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—RXRA—thyroid cancer	7.13e-06	0.000487	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NRG1—thyroid cancer	7.12e-06	0.000486	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDK1—thyroid cancer	7e-06	0.000478	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NRG1—thyroid cancer	6.81e-06	0.000465	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TERT—thyroid cancer	6.42e-06	0.000439	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SLC5A5—thyroid cancer	6.4e-06	0.000437	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TERT—thyroid cancer	6.39e-06	0.000436	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—KRAS—thyroid cancer	6.38e-06	0.000436	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PPARG—thyroid cancer	6.22e-06	0.000425	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NRG1—thyroid cancer	6.18e-06	0.000422	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HIF1A—thyroid cancer	6.14e-06	0.00042	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TERT—thyroid cancer	6.12e-06	0.000418	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HIF1A—thyroid cancer	6.11e-06	0.000417	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NRG1—thyroid cancer	6.05e-06	0.000413	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SLC5A5—thyroid cancer	6.03e-06	0.000412	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HIF1A—thyroid cancer	5.85e-06	0.0004	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—thyroid cancer	5.67e-06	0.000387	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NRG1—thyroid cancer	5.62e-06	0.000384	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TERT—thyroid cancer	5.55e-06	0.000379	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TERT—thyroid cancer	5.43e-06	0.000371	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—HRAS—thyroid cancer	5.42e-06	0.00037	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—NRAS—thyroid cancer	5.41e-06	0.00037	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—NRAS—thyroid cancer	5.38e-06	0.000368	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—RXRA—thyroid cancer	5.38e-06	0.000367	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	5.31e-06	0.000362	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TPR—thyroid cancer	5.27e-06	0.00036	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	5.2e-06	0.000355	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.18e-06	0.000354	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	5.15e-06	0.000352	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—BRAF—thyroid cancer	5.09e-06	0.000347	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—RXRA—thyroid cancer	5.07e-06	0.000346	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—BRAF—thyroid cancer	5.06e-06	0.000346	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TERT—thyroid cancer	5.05e-06	0.000345	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—thyroid cancer	4.91e-06	0.000335	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—thyroid cancer	4.9e-06	0.000334	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	4.84e-06	0.000331	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	4.83e-06	0.00033	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—AKT1—thyroid cancer	4.79e-06	0.000327	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	4.68e-06	0.000319	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	4.66e-06	0.000318	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	4.63e-06	0.000316	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	4.58e-06	0.000313	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—thyroid cancer	4.5e-06	0.000307	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	4.44e-06	0.000303	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BRAF—thyroid cancer	4.39e-06	0.0003	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	4.3e-06	0.000294	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTEN—thyroid cancer	4.27e-06	0.000292	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	4.25e-06	0.00029	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	4.02e-06	0.000275	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	4e-06	0.000273	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	3.96e-06	0.00027	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.94e-06	0.000269	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	3.94e-06	0.000269	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	3.94e-06	0.000269	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—thyroid cancer	3.86e-06	0.000264	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	3.85e-06	0.000263	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	3.83e-06	0.000262	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	3.77e-06	0.000257	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—thyroid cancer	3.71e-06	0.000254	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—thyroid cancer	3.69e-06	0.000252	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	3.67e-06	0.00025	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	3.66e-06	0.00025	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—thyroid cancer	3.58e-06	0.000245	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—thyroid cancer	3.56e-06	0.000243	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—thyroid cancer	3.54e-06	0.000242	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	3.54e-06	0.000241	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	3.5e-06	0.000239	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	3.48e-06	0.000238	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	3.42e-06	0.000234	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	3.41e-06	0.000233	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—thyroid cancer	3.39e-06	0.000232	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—thyroid cancer	3.37e-06	0.00023	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	3.35e-06	0.000229	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	3.33e-06	0.000227	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	3.33e-06	0.000227	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—RXRA—thyroid cancer	3.31e-06	0.000226	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	3.26e-06	0.000222	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—thyroid cancer	3.21e-06	0.000219	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—thyroid cancer	3.2e-06	0.000218	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NRAS—thyroid cancer	3.2e-06	0.000218	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NRAS—thyroid cancer	3.18e-06	0.000217	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	3.14e-06	0.000214	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	3.11e-06	0.000213	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—thyroid cancer	3.1e-06	0.000211	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—thyroid cancer	3.09e-06	0.000211	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	3.04e-06	0.000208	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	3.03e-06	0.000207	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	3.03e-06	0.000207	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	3.02e-06	0.000206	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	2.96e-06	0.000202	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	2.92e-06	0.000199	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	2.82e-06	0.000192	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NRAS—thyroid cancer	2.76e-06	0.000189	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—thyroid cancer	2.75e-06	0.000188	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	2.75e-06	0.000188	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—thyroid cancer	2.74e-06	0.000187	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	2.7e-06	0.000185	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—thyroid cancer	2.67e-06	0.000182	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	2.62e-06	0.000179	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—thyroid cancer	2.52e-06	0.000172	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	2.51e-06	0.000172	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—thyroid cancer	2.46e-06	0.000168	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—thyroid cancer	2.45e-06	0.000167	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—thyroid cancer	2.43e-06	0.000166	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—thyroid cancer	2.38e-06	0.000162	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—thyroid cancer	2.34e-06	0.00016	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—thyroid cancer	2.33e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—thyroid cancer	2.33e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	2.33e-06	0.000159	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—thyroid cancer	2.33e-06	0.000159	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	2.23e-06	0.000152	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—thyroid cancer	2.19e-06	0.00015	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	2.16e-06	0.000148	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—thyroid cancer	2.11e-06	0.000144	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—thyroid cancer	2.09e-06	0.000143	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—thyroid cancer	2.07e-06	0.000141	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—thyroid cancer	2.07e-06	0.000141	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—thyroid cancer	2.05e-06	0.00014	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—thyroid cancer	2.02e-06	0.000138	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	1.98e-06	0.000135	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	1.97e-06	0.000134	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—thyroid cancer	1.94e-06	0.000133	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—thyroid cancer	1.92e-06	0.000131	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	1.84e-06	0.000126	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—thyroid cancer	1.78e-06	0.000122	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—thyroid cancer	1.78e-06	0.000121	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	1.75e-06	0.000119	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.65e-06	0.000112	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	1.62e-06	0.000111	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—thyroid cancer	1.43e-06	9.8e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—thyroid cancer	1.34e-06	9.17e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—thyroid cancer	1.26e-06	8.64e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—thyroid cancer	8.27e-07	5.65e-05	CbGpPWpGaD
